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Bcl-2Ceramide is a bioactive sphingolipid involved in mitochondrial-mediated apoptosis. Our data suggest that
ceramides directly regulate a key initiation step in apoptosis: mitochondrial outer membrane permeabilization
(MOMP). MOMP allows release of intermembrane space proteins to the cytosol, inducing the execution of the
cell. Ceramides form channels in planar phospholipid membranes and outer membranes of isolated mitochon-
dria, channels large enough to facilitate passage of proteins released during MOMP. Bcl-xL inhibits MOMP
in vivo and inhibits the formation of ceramide channels in vitro. However the signiﬁcance of Bcl-xL's regulation
of ceramide channel formation within cells was untested.We engineered Bcl-xL pointmutations that speciﬁcally
affect the interaction between ceramide and Bcl-xL to probe the mechanism of ceramide channel regulation and
the role of ceramide channels in apoptosis. Using these mutants and ﬂuorescently-labeled ceramide, we identi-
ﬁed the hydrophobic groove on Bcl-xL as the critical ceramide binding site and regulator of ceramide channel for-
mation. Bcl-xL mutants with weakened interaction with ceramide also have reduced ability to interfere with
ceramide channel formation. Somemutants have similar altered ability to inhibit both ceramide and Bax channel
formation, whereas others act differentially, suggesting distinct but overlapping binding sites. To probe the rela-
tive importance of these channels in apoptosis, Bcl-xL mutant proteins were stably expressed in Bcl-xL deﬁcient
cells. Weakening the inhibition of either Bax or ceramide channels decreased the ability of Bcl-xL to protect cells
from apoptosis in a stimulus-dependent manner. These studies provide the ﬁrst in vivo evidence for the role of
ceramide channels in MOMP.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The release of mitochondrial intermembrane space (MIS) proteins
into the cytosol is a key decision-making step in the apoptotic process.
The released proteins initiate the execution phase of apoptosis via a se-
ries of steps that ultimately lead to the activation of caspases, speciﬁc
proteases that lead to the transformation of the cell into apoptotic bod-
ies that are engulfed by phagocytes. Variousmechanisms exist bywhich
proteins can be released from the MIS [1–4]. Some of these involve the
formation of large channels in the mitochondrial outer membrane
(MOM). Two such channels are formed by either the translocation to
the MOM and oligomerization of a cytosolic protein called Bax or the
self-assembly of a MOM lipid called ceramide [5–9]. Bax is a membernal Science Foundation MCB-
Digestive and Kidney Diseases
.J.S.), and the Kosair Pediatric
University of Maryland, Collegeof the Bcl-2 family of proteins that regulate apoptosis [10–12]. Both
Bax and Bak are pore-forming proapoptoticmembers of this family. Cer-
amide is a pore-formingmember of the sphingolipid family of cell lipids,
some of which are involved in the apoptotic process [13]. The functions
of Bax, Bak and ceramide are interdependent in a number of ways. In
some systems, the induction of apoptosis by ceramide requires the pres-
ence of Bax [14,15]. The Bak protein is required for ceramide synthase-
dependent long-chain ceramide synthesis during apoptosis [16]. There
is evidence for synergy between Bax and ceramide in MOM perme-
abilization (MOMP) in isolated mitochondria [17,18].
The role of Bax in MOMP is well established [12] although the struc-
ture of the Bax channels is only poorly understood [19]. Ceramide's role
in inducing apoptosis is also widely acknowledged [20,21] although its
ability to directly form channels in theMOM is still viewed with skepti-
cism. Published work strongly supports the ability of ceramide to form
channels in theMOMatphysiologically relevant concentrations [4]. Cer-
amide forms large channels (typically 10 nm in diameter) in phospho-
lipid membranes lacking proteins and these have been visualized by
electron microscopy [22]. It has also been shown to release a variety
of MIS proteins from isolated mitochondria while not releasing matrix
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simulations [24] support amodel of the ceramide channels that consists
of barrel-like structure whose staves are membrane-spanning strings of
ceramide molecules organized in an anti-parallel manner (S1). These
thin-walled pores behave like elastic discs that can be deformed but
will regain their natural structure after relaxation [25]. Yet all evidence
indicates [5] that they are in dynamic equilibrium with ceramide
monomers or non-conducting ceramide assemblies. Thus, there is
a great deal of dynamic motion and structural changes associated
with these channels.
The formation of both Bax and ceramide channels is inhibited by the
anti-apoptotic protein, Bcl-xL [26,27]. Whereas, it is generally agreed
that Bcl-xL inhibits Bax channel formation by forming heterodimers
with activated Bax monomers [27,28], the mechanism by which Bcl-xL
inhibits ceramide channels is notwell understood. Since ceramide chan-
nels are large assemblies of ceramide monomers, there is no precedent
to indicate possible mechanisms by which such a structure could be
prevented from forming or be destabilized by a protein although a
mechanism has been proposed [29]. Experiments with ceramide ana-
logs demonstrated that the hydrophobic tails of ceramide are important
for the inhibition by Bcl-xL [29]. In addition, small molecule inhibitors
(2-methoxyantimycin A3, ABT-737 and ABT-263), known as BH3 pep-
tide mimetics because they bind to a hydrophobic grove on Bcl-xL and
thus block its ability to bind to Bax, were also found to inhibit the ability
of Bcl-xL to inhibit the formation of ceramide channels in theMOM [29].
These inhibitors interfere with the anti-apoptotic activity of Bcl-xL
[30–32] suggesting that the ability of Bcl-xL to interfere with ceramide
channel formation may somehow be linked to its anti-apoptotic func-
tion. Here we provide insight into the molecular basis by which Bcl-xL
acts to inhibit ceramide channels by providing evidence for direct bind-
ing and using point mutations to identify the region on Bcl-xL responsi-
ble for the inhibition. These same Bcl-xL mutants were expressed in
cells lacking Bcl-xL to assess the importance of ceramide channels in
the in vivo apoptotic process.
2. Materials and methods
2.1. Isolation of rat liver mitochondria
Mitochondria were isolated from the liver of male Sprague Dawley
rats as described originally [33] and as modiﬁed [29]. The animal use
protocols were approved by the Institutional Animal Care andUse Com-
mittee. The animalswere euthanized by a procedure consistentwith the
Panel on Euthanasia of the AVMA (American VeterinaryMedical Associ-
ation). The animal facility used to house the animals is accredited by
AAALAC (Association for Assessment and Accreditation of Laboratory
Animal Care).
2.2. Puriﬁcation of recombinant proteins
The construct of full-length human Bcl-xL (Bcl-xL wild-type), Bax
and t-Bid were gifts from Dr. Marie Hardwick, Dr. Richard Youle and
Dr. Donald Newmeyer, respectively. All single mutations of Bcl-xL
were introduced using QuickChange Site-Directed Mutagenesis kit
(Stratagene) and veriﬁed by DNA sequencing. Recombinant Bcl-xL and
its mutants were puriﬁed as previously described [34] and as modiﬁed
[29]. In brief, GST-tagged Bcl-xL and GST-tagged Bid were produced in
BL21(DE3) pLysS. The cells were induced with 10 μM IPTG for 2 h at
37 °C for GST-tagged Bcl-xL and the cells were induced with 0.4 mM
IPTG for 3 h at 37 °C for GST-tagged Bid, resuspended in PBS with
1.25 kU/L cells of lysozyme and 35 μM PMSF and lysed using a French
press. After removal of cell fragments, the GST-tagged Bcl-xL and GST-
tagged t-Bid were puriﬁed using glutathione agarose beads and the
GST tag was cleaved with 5 U biotinylated thrombin which was re-
moved using streptavidin beads. Recombinant human Bax was puriﬁed
using a chitin column (New England Biolabs Inc.) and dialyzed with a12,000 MW cut-off dialysis membrane to remove dithiothreitol [17,35,
36]. All puriﬁed proteins were supplemented with glycerol to 10% and
ﬁltered sterilized through a 0.2 μm ﬁlter prior to being rapidly shell-
frozen in ethanol and dry ice and stored at−80 °C. The concentration
of proteins was determined with a MicroBCA Protein Kit (Pierce
Chemical).
2.3. Binding of ceramide to Bcl-xL
Nine microliters of ﬂuorescently-labeled ceramide (C11 TopFluor
ceramide; Avanti Polar Lipids) dissolved in isopropanol at 42 μg/ml
was dispersed to 590 μl containing 1.8 μM Bcl-xL wild-type or its
mutants in 20mMTris, pH7.4, 10% sucrose. The dispersalwas performed
by slow delivery of the ceramide solution into the protein solutionwhile
it was being vortexed. Entrainment of air was carefully avoided. In order
to remove ceramidemicelles, 50 μl of 20mMTris, pH 7.4, 5% sucrosewas
applied to the top of themixture to produce a density gradient. Then the
gradient was spun in MLA-130 at 55,000 rpm at 25 °C for 30 min. Cer-
amide micelles ﬂoat into the upper layer and so a portion of the solution
in the 10% sucrose phase was removed, excited by 490 nm incident light
and the emission spectrum from 495 to 520 nm was recorded in a
FluoroMax-4. The ﬂuorescencewas not detected in the non-protein con-
trols, so all ﬂuorescence was due to ceramide associated with protein.
The ﬂuorescent quantum yield of the bound ceramide varied depending
on the protein used. Thus, in order to assess the amount of ceramide
bound, a portion of the ﬂuorescent solution was mixed with the same
volume of isopropanol (to denature the protein and extract the cer-
amide) and spun at 18,000 rcf at 4 °C for 40min. The emission spectrum
of the supernatant was recorded.
2.4. Cytochrome c accessibility assay
The rate of oxidation of exogenous reduced cytochrome c by
cytochrome c oxidase in the isolated mitochondria indicates the perme-
ability of the MOM, because translocation through the outer membrane
is a rate limiting step [37]. The procedure used was as previously
described [29] except that different concentrations of Bcl-xL and its
mutants were mixed with isolated mitochondria in reaction buffer
(280 mM mannitol, 0.1 mM EGTA, 5 mM HEPES, pH 7.25, 5 mM,
2,4-Dinitrophenol and 1.3 μM antimycin A) before N-palmitoyl-D-
erythro-sphingosine (C16-ceramide) dispersal. The amount of cytochrome
c that was oxidized was determined by measuring the change in
absorbance 550 nm and quantitated using an extinction coefﬁcient
of 18.5 mM−1·cm−1 (the difference between the reduced and oxidized
form). At dose used there is no signiﬁcant effect of antimycin A of the
ability of Bcl-xL to inhibit ceramide [29].
2.5. Adenylate kinase assay
This assay measures the release of adenylate kinase from the MIS.
This indicates the portion of mitochondria whose outer membrane
wasmade permeable to proteins. The procedure was performed as pre-
viously described [38] except that the ﬁnal concentration of KCl was
kept at 60 mM. This assay was used to assess the permeabilization of
the MOM by Bax.
2.6. Molecular dynamic simulations
The structure of full-length Bcl-xL-ceramide assembly was based on
the published model from MD studies [29] that were performed using
the crystallographic structure of the Bcl-xL/Bim fragment complex
(PDB ID: 1PQ1). In the experimental setting, the N-terminal part of
Bcl-xL is preceded by a few extra amino acids (GSPRRS) inherited
after thrombin cleavage. To better match with the experiments, we
attached this fragment to N-terminus of Bcl-xL (however being so
remote from the ceramide binding site, this modiﬁcation should not
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tal structure (residues 29 to 77) as well as the added N-terminal frag-
ment were modeled using Robetta [39]. N- and C-termini of the ﬁnal
Bcl-xL structure were modeled in the dissociated state.
The complete system (96,080 atoms) contained 3686 protein atoms
(239 residues), 106 atoms of C16-ceramide (one residue), and 2392
atoms of D-mannitol (92 residues — matching 160 mM mannitol in
the experimentalmedium). Tomaintain the electroneutrality of the sys-
temK+ and Cl− ionswere added up to an equivalent of 60mMsalt con-
centration, 43 K+ and 34 Cl− . Assembly of the simulation system,
introduction of the single mutations into the Bcl-xL structure (see the
main text), analysis of the results and visualization were performed in
VMD v1.9 [40] using custom-written Tcl scripts.
MD stimulations were done using the NAMD package [41]. All the
simulationswere performed as an NPT ensemble using the CHARMM36
force ﬁeld [42] and TIP3P water model [43]. Parameters for ceramide
were taken from the previously published simulations [24]. The acidic
and basic residues of Bcl-xL were set in their default protonation state
at pH 7.0 (estimated using PROPKA for neutral pH [44]). Langevin Dy-
namics [45,46] was used to maintain constant pressure (1 atm) and
constant temperature (295.15 °K). Periodic boundary conditions were
maintained and the particle mesh used the Ewald method [47] with a
real space cutoff distance of 1.2 nm and a grid width of 0.1 nm. Energy
Minimization steps were performed using the steepest descent in the
ﬁrst 2000 steps and then a conjugate gradient in the subsequent 2000
steps. To attain the equilibrium, the system was subjected to gradual
heating until it reached to 295.15 K (22 °C), ﬁrst with the protein back-
bone harmonically restrained (100 kcal/mol/nm2 per backbone atom)
to the initial coordinates for 1 ns, then simulated unrestrained for 30 ns.
2.7. Statistics for all studies except the whole-cell experiments
The results are reported as the mean ± SE of at least 3 independent
experiments. Signiﬁcance was determined by using the Student's t-test.
Single, double, triple and quadruple symbols, indicate signiﬁcance with
P-values b 0.05, b0.01, b0.001 and b0.0001 respectively.
2.8. Cell culture
Mouse embryonic ﬁbroblast (MEF) Bcl-x-KO cell line was kindly
provided by Dr. Chi Li (University of Louisville, Louisville, KY) [48].
Cells were maintained in DMEM (Thermo Scientiﬁc, SH30243.01) con-
taining 10% FBS (Thermo Scientiﬁc, SH30070.03) supplemented with
1× pen-strep (Gibco 15140-122). Cells were routinely tested to verify
that they were free of mycoplasma infection.
2.9. Generation of cell lines
Full length human Bcl-xL cDNA and single point mutation Bcl-xL
mutants (generated by using QuickChange II XL Site-DirectedMutagen-
esis kit from Agilent Technologies, # 200521-5 and veriﬁed by DNA se-
quencing) were cloned into the GFP expressing mammalian expression
retroviral vectorMIGRX EcoRI/XhoI to generate MIG-Bcl-xL or MIG-Bcl-
mutant plasmids. MEF Bcl-xL-KO cells were infected with viruses ex-
pressing these mutants and infected cell populations were selected by
sorting of GFP expressing cells by ﬂow cytometry to generate stable
cell lines. Presence of Bcl-xL WT and mutants in MEF-Bcl-xL-KO stable
cell lines was conﬁrmed by western blot as described below.
2.10. Western blot
Cell pellets were collected and lysed in NP-40 lysis buffer (Boston
BioProducts, BP-119). Protein concentrations were determined using
BCA protein assay reagent (Pierce #23223 and #23224). Twentymicro-
grams of protein samples were loaded on a 4–12% Bolt Bis-Tris Plus gel
(Life technologies, BG04120BOX) and transferred to PVDF membrane(Bio-Rad, #162-0177). Membranes were blocked in TBS-T with 5%
milk for 1 h at room temperature.Membraneswere incubated overnight
at 4 °C with primary antibodies; anti-Bcl-xL (54H6) (Cell signaling, #
2764), anti-GFP (Abcam, ab6673) and anti-tubulin (Sigma Aldrich,
#T5168) at 1: 20,000 dilutions. Anti-mouse and anti-rabbit peroxidases
labeled secondary antibodieswere added at a dilution of 1:40,000 for 1 h
at room temperature. Chemiluminescent detection was performed
using Pierce ECL Western Blot Substrate (Thermo Scientiﬁc, #32106).
2.11. Cell viability assay
MEF cells were cultured in 96-well plates (2500 cells per well) over-
night and then treatedwith different apoptotic stimuli at indicated drug
concentrations for 24 h. Cells were then incubated with 10% Alamar
Blue reagent (Invitrogen, DAL1100) for 4 h and the ﬂuorescence of
Alamar Blue reduction was determined using BioTek HT Synergy plate
reader (540 nmexcitation, 594 nmemission). Relative viability of treat-
ed cells was calculated by normalizing to vehicle treated cells. For bar
graphs, relative cell viability was presented as normalized with respect
toWT at that dose of a drug. Cisplatin (#4394), Thapsigargin (# T9033),
Etoposide (#, E1383) and Gemcitabine (#, G6423) were purchased
from Sigma. Hydrogen peroxide was purchased from Fisher scientiﬁc
(# H325-100). Doxorubicin (#, 15007) was purchased from Cayman
chemical company. Bortezomib was purchased from ChemieTek (#,
CT-BZ001). All treatments were done in triplicate and each graph
shown is a representative experiment of at least three biological repli-
cates. Statistical analysis was performed using one-way ANOVA with
Tukey's test. p b 0.05 was considered signiﬁcant.
3. Results
Previous studies demonstrated that Bcl-xL inhibits ceramide channel
formation in isolatedmammalianmitochondria [26,29]. In addition, the
use of ceramide analogs indicated that the hydrophobic regions of cer-
amide are important for this action of Bcl-xL [29]. To distinguish be-
tween direct and indirect action, it would be desirable to determine
whether Bcl-xL binds a ceramide channel. However, direct binding
studies are not possible because ceramide channels are in dynamic
equilibrium with ceramide monomers [5] and thus cannot be isolated
and puriﬁed. The possibility of examining the binding of Bcl-xL to cer-
amide channels formed in liposomes is also not feasible because Bcl-
xL binds tomembranes regardless of the presence of ceramide channels
and current methods of generating ceramide channels in liposomes
cause only partial release of contents indicating that only one channel
is formed per liposome [49,50]. Thus any binding studies would be
plagued by very low signal to noise ratios. An alternative method is to
determine whether a ceramide molecule is capable of binding to Bcl-
xL. The binding of a ceramidemolecule to Bcl-xLmaymimic the binding
between Bcl-xL and ceramide channels.
3.1. Binding of ceramide to Bcl-xL
Binding studies between Bcl-xL and ceramide are complicated by
the physical properties of ceramide. Ceramide is inherently insoluble
in water and Bcl-xL cannot be expected to function normally in an or-
ganic solvent. Therefore, an equilibrium binding experiment is not pos-
sible. However, when ceramide dissolved in isopropanol is dispersed in
an aqueous environment, ceramidemolecules exist transiently in aque-
ous solution and these can either bind to Bcl-xL or combine with each
other to form micelles. If the Bcl-xL/ceramide complex is formed it is
unlikely to dissociate because of ceramide's insolubility in water. Thus
the complex should be stable and can be detected. However, a binding
constant cannot be determined. Thus ﬂuorescently-labeled ceramide
(C11 TopFluor ceramide) was dispersed into a solution containing Bcl-
xL (Fig. 1A). Any ﬂuorescent ceramide that does not bind must form
micelles. The ﬂuorescent ceramide micelles were removed by
Fig. 1. Fluorescently-labeled ceramide binds to Bcl-xL. A. Separation of ﬂuorescently-labeled ceramide bound Bcl-xL from ceramide micelles. F1 is ﬂuorescently-labeled ceramide: C11
TopFluor ceramide. B. Fluorescence spectrum of ﬁnal sample from the separation shown in “A” (see Materials and Methods for details). “WT” indicates the medium contained wild-
type Bcl-xL and ﬂuorescence was due to bound ﬂuorescently-labeled ceramide. “buffer” indicates that there was no Bcl-xL in that separation procedure. The lack of ﬂuorescence indicates
that the procedure was effective at eliminating ceramide micelles. The inset is the structure of ﬂuorescently-labeled ceramide.
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micelles is less than that of the aqueous solution and this difference
was increased by using 10% sucrose. The ﬂuorescence of the sub-
phase was recorded. In the absence of Bcl-xL, the centrifugation
cleared the solution of ceramide micelles resulting in no detectable
ﬂuorescence. However, in the presence of Bcl-xL substantial ﬂuores-
cence was recorded (Fig. 1B). The results indicate that the ceramide
molecule binds to Bcl-xL directly.
3.2. Determination of the location of the binding region on Bcl-xL
Previous studies showed that drugmolecules that bind to hydropho-
bic groove on Bcl-xL (ABT-263 and ABT-737) interfered with the
protein's ability to inhibit ceramide channel formation [29]. Thus this
region of Bcl-xL is a good candidate for the putative binding site by
which Bcl-xL inhibits ceramide channels. To identify residues in the hy-
drophobic groove that may be important in regulation of ceramide
channels, molecular docking of a ceramide molecule to Bcl-xL was con-
ducted and two low-energy modes were used (pose1 and 2) [29]
(Fig. 2A). Single amino acid substitutions were made so as to change
the strength of the interaction at the putative docking sites. Changes
in charge (E96L and R100L), polarity (F97Q, F105Q, V126Q), andFig. 2. A. One docking pose of ceramide on the crystal structure of Bcl-xL. The amino acids to be
ceramide amide linkage is in themiddle with the amide nitrogen in blue and the carbonyl oxyg
abilization of the MOM to cytochrome c estimated by measuring the initial rate of oxidation of
pension was added 15 μL of either isopropanol (iso) or C16 ceramide (cer). The results were no
mitochondria had been preincubated for 5 min with 47 nMwild-type Bcl-xL or the respectivephysical volume (V126W, F146A, Y195A) were engineered into full-
length Bcl-xL (Fig. 2A). These were tested in isolated mitochondria for
their ability to interfere with ceramide channel formation.
As illustrated in Fig. 2B, the amount of reduced cytochrome c in the
medium decreased as the added mitochondria oxidized the protein.
The cytochrome c could only be oxidized if it could cross the outermem-
brane andbind to cytochrome c oxidase on the outer surface of the inner
membrane. Thus the rate of oxidation of the cytochrome c is related to
the degree of MOMP by ceramide channels. The baseline rate of oxida-
tion occurred when the vehicle (isopropanol) was added to the mito-
chondria. When ceramide dissolved in isopropanol was dispersed into
the mitochondrial suspension, the rate of oxidation increased. This rate
was diminished by the presence of Bcl-xL in the medium. Many of the
altered proteins had lost some of their ability to inhibit ceramide-
induced MOMP, but one mutant was actually a more potent inhibitor
than the wild-type. In order to achieve a greater dynamic range, exper-
imentswere performed at two levels of added Bcl-xL protein: a low level
resulting in aweaker inhibition (i.e. a greater ceramide-inducedMOMP)
to detect mutant proteins that had a stronger inhibition than the wild
type, and a high level to detect mutants with a weaker inhibitory affect.
Fig. 3A and B show themeasured % inhibition for one set of experiments
using 0.72 and 2.1 μMBcl-xL protein, respectively. Note that the strongermutated are illustrated (yellow). Ceramide is in green with the two chains speciﬁed. The
en in red. The pose was obtained from the publication of Perera et al., 2012 [29]. B. Perme-
added cytochrome c (24.7 μM ﬁnal). To 730 μL of 0.25 mg/mL rat liver mitochondrial sus-
rmalized by the absorbance of cytochrome c at zero time.WT, F105Q, R100L indicated that
mutants.
Fig. 3. The inhibitory potency of Bcl-xL mutants on ceramide channels formed in isolated mitochondria. The ﬁnal concentration of added Bcl-xL or mutant proteins was 0.72 μM (A) and
2.1 μM (B). C. Relative inhibition of ceramide inducedMOMP by Bcl-xL mutants. The inhibitory ability is expressed relative to that of thewild-type so that if it is the same as thewild type
the result would be 1. As indicated in the text, this corrects both for variability from experiment to experiment and for the use of different concentrations of protein to reveal changes in
inhibitory potency of both the weak and strong mutants. The statistically signiﬁcant differences from the potency of the wild-type are indicated by the asterisk.
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and the weaker inhibitors were apparent at the higher protein concen-
tration. Since experiments with wild-type and mutant Bcl-xL were per-
formed in parallel, the level of inhibition of the ceramide channels was
normalized to that of the wild-type protein (Fig. 3C) and then data
from independent experiments was pooled and averaged. This normal-
izationwas necessary because the potency of the Bcl-xL varied from one
batch of isolatedmitochondria to another. The data for the enhanced in-
hibition came from the low Bcl-xL concentration experiments whereas
thedata for the reduced inhibition came from thehigh concentration ex-
periments. The mutants are organized in a pattern reﬂecting their loca-
tion on the docking site (Fig. 2A). The results follow a distinct pattern.
All but one of themutants (E96L) were able to inhibit the formation
of ceramide channels, the difference being the amount of protein need-
ed to achieve the same level of inhibition. Thus perhaps E96 is such a
critical site that removal of the carboxyl group results in failure to
bind ceramide. V126W was nearly as effective as the wild-type, as ex-
pected from themild change in the structure of the side chain. The inhi-
bition capability of F97Q, R100L, F105Q, F146A and Y195A was weaker
than that of thewild typewhereas the capability of V126Qwas stronger.
From the docking pose, R100 hydrogen bonds with the C3 hydroxyl of
ceramide. The samewas seen in the MD simulations (S2). The hydroxyl
group of tyrosine 195 interacts with the carbonyl of ceramide in the
docking experiment whereas the MD simulations show intimate di-
pole–dipole interactions between this hydroxyl and the C1 hydroxyl
of ceramide (S1A). Thus the weaker interaction of these mutations cor-
relates with the structural information provided by theMD simulations.
F97Q, F105Q and F146A disrupted hydrophobic interactions suggesting
that these residues interact with the hydrophobic tails of ceramide.These results agreewith one of the Bcl-xL/ceramide binding poses iden-
tiﬁed in the docking studies. In theMD simulations these three residues
form the major portion of the hydrophobic surface that interacts with
the ceramide acyl chain again conﬁrming the importance of retaining
these apolar surfaces (S1B).
3.3. Correlation between the quantum yield of ﬂuorescent ceramide bound
to Bcl-xL mutants and their ability to inhibit MOMP
The Bcl-xLmutants were tested for their ability to bind ﬂuorescently
labeled ceramide as was performed in Fig. 1. Direct binding measure-
ments did not yield satisfactory results for 2 reasons: 1) The variability
in the ceramide dispersion process resulted in variable amounts of bind-
ing. 2) The unidirectional nature of the binding process in aqueous solu-
tion means that changes in the rates of dissociation could not affect the
amount of binding. However, in attempting these experiments it was
noted thatﬂuorescently labeled ceramide bound tomutated Bcl-xL pro-
duced much less ﬂuorescence than the same ceramide bound to wild-
type Bcl-xL. Fig. 4A shows the reduction of ceramide ﬂuorescence
upon binding to Bcl-xL. The solid circles show the spectrum of the cer-
amide bound to the Bcl-xL, whereas the open circles show the spectrum
after extraction with isopropanol. These relative values were adjusted
for the volume of the solution. The reduction in ﬂuorescence is probably
the result of exposing the ﬂuorophore to a polar environment that
quenches the ﬂuorescence. Fig. 4B shows the ﬂuorescent intensity of
the same amount of ceramide bound to either wild-type Bcl-xL or Bcl-
xL mutants. This difference is most likely due to greater interaction of
the ﬂuorophore with water. In a tight-binding situation water will
have less contactwith the ﬂuorophore and thus result in less quenching.
Fig. 4. A. Fluorescence spectrum of C11 TopFlour bound to Bcl-xL (WT+ Cer), C11 TopFlour extractedwith isopropanol (WT extracted), and controls lacking Bcl-xL. B. Fluorescence spec-
trum of C11 TopFlour bound towild-type Bcl-xL (WT) and to various Bcl-xLmutants. The curveswere normalized by theﬂuorescence of the extracted ﬂuorescent ceramide. Thus changes
in ﬂuorescence intensity were due to reductions in the quantumyield due to some quenching process. C. Correlation between the quenching of ﬂuorescent ceramide bound to Bcl-xLmu-
tant protein and the ability of the same protein to inhibit ceramide permeabilization of the MOM.
Fig. 5. Correlation between the dynamic motion of the ceramide molecule and the ability
of a Bcl-xL mutant to inhibit ceramide permeabilization of theMOM. Themobility (RMSF)
of regions of the ceramide molecule (inset) were measured. Those regions surrounded by
a solid line are plotted as a solid line in themain ﬁgure. Similarly for the dotted and dashed
line. The inhibitory ability (horizontal axis) is expressed relative to that of thewild-type so
that if it is the same as the wild type the result would be 1.
2379K.-T. Chang et al. / Biochimica et Biophysica Acta 1848 (2015) 2374–2384There is a good correlation between the intensity of the measured ﬂuo-
rescence and the potency of themutant (Fig. 4C) to destabilize ceramide
channels. These results indicate that binding of Bcl-xL to the ceramide
channel was the basis for the inhibitory effect and thus the ceramide
channel was being directly controlled by this anti-apoptotic protein.
3.4. Molecular dynamic simulations of ceramide binding to Bcl-xL
Wild type Bcl-xL and 5 mutants (E96L, R100L, F105Q, V126Q and
Y195A) that span the range of abilities to inhibit ceramide perme-
abilization of the MOM, were examined using MD simulations to
explore their interaction with a C16-ceramide molecule. In the ﬁrst
few nanoseconds of simulation the ceramide found its optimal position
in the Bcl-xL hydrophobic pocket and from then on the positions varied
according to local interactions with the Bcl-xL protein and the water
environment. All the introduced mutations are among the residues
that are likely to interact with ceramide; they do not participate in
any signiﬁcant inter-helical interactions that maintain protein fold.
Therefore, themutants are not likely to affect theprotein structure itself.
Indeed, in simulations the structure of the ceramide-binding region of
Bcl-xL changed very little in the mutants compared to the wild-type
(0.15 ± 0.04 nm all-mutant mean deviation of the backbone from
the WT position) indicating that the mutations acted locally, on the
protein-ceramide interactions rather than globally, through a change
in the protein structure. However the results showed considerable
changes in the location and dynamics of the bound ceramide−1.0 ±
0.3 nm all-mutant mean deviation of ceramide from its average position
in WT Bcl-xL. The dynamic motion of the ceramide molecule (S3) corre-
lates verywellwith the loss of ability to inhibit ceramide permeabilization
(Fig. 5, Table 1), i.e. ceramide channel formation. The highest correlationwas observed when the distal half of the sphingosine acyl chain was ex-
cluded. Theﬂuorophore label experiencingmore quenchingwith reduced
inhibitory ability of the Bcl-xLmutant agreeswith the simulation ﬁndings
of greater mobility. Greater mobility should result in more access to
water dipoles and thus more water-induced quenching. Note that the
ﬂuorophore is on the fatty acyl chain whose mobility correlates well
with loss of Bcl-xL inhibitory ability.
The relative location of the ceramide on Bcl-xL compared to the wild-
type also correlates, although more weakly, with the loss of inhibitory
Table 1
Correlation between the dynamic motion (RMSF) of different regions of the ceramide molecule and the ability of Bcl-xL to inhibit ceramide permeabilization of the MOM.
Mobility Deviation from wild type
Location Correlation Location Correlation
Ceramide without sphingosine tail after C10 −0.96 Ceramide amide oxygen −0.63
Ceramide up to C10 and C8′ −0.96 Ceramide polar atoms −0.60
Ceramide amide tail C9′–C16′ −0.91 Ceramide headgroup −0.59
Ceramide whole −0.78 Ceramide fatty acid residue −0.57
Ceramide tail C10–C8′ −0.57 Ceramide amide tail −0.54
Bcl-xL −0.09 Ceramide whole −0.24
Bcl-xL in contact with Ceramide −0.07
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ability of the bound Bcl-xL to destabilize the channel.
3.5. Comparison of the binding footprint on Bcl-xL of Bax and the ceramide
channel
Bcl-xL is known to inhibit the formation of Bax channels in themito-
chondrial outer membrane. The hydrophobic pocket of Bcl-xL binds the
BH3 domain of pro-apoptotic proteins such as Bax and Bid [27,28,51]
and thus inhibits their pro-apoptotic activity, including channel forma-
tion. The Bcl-xLmutantswere tested for their effects on Bax channel for-
mation in the MOM to determine if their relative potency is similar to
that observed for ceramide channels. A complicating factor is that trun-
cated Bid (t-Bid) is necessary to activate Bax resulting in MOMP and
thus one cannot distinguish between an inhibitory effect on Bax or onFig. 6. The inhibitory potency of Bcl-xL mutants on Bax permeabilization of the MOM. The ﬁna
inhibition of Bax permeabilization of MOM by Bcl-xL mutants. The inhibitory ability is expre
would be 1. The statistically signiﬁcant difference from the potency of the wild-type is indicatet-Bid. Regardless of which protein binds to Bcl-xL, the mutants will
probe whether the same region of Bcl-xL is used in both cases. Once
again, in order to achieve a greater dynamic range, the amount of wild
type protein addedwas adjusted to obtain aweaker (Fig. 6A) or a stron-
ger (Fig. 6B) inhibition. The results show that V126Q and Y195A have a
stronger inhibitory effect than the wild-type. F146A, R100L, V126W,
F105Q, F97Q and E96L have a weaker inhibitory effect. As in the case
of the ceramide channel, E96L has no effect. A comparison of the inhib-
itory effects of mutated Bcl-xL on Bax (Fig. 6C) and ceramide channels
(Fig. 3C) reveals that two mutations have distinctly different effects on
the two channels. A plot of one set of data vs the other (Fig. 7) shows
that Y195A has stronger inhibition of Bax channels as compared to the
wild-type protein but a weaker inhibitory effect on ceramide channels.
V126Wwas not able to inhibit Bax channels aswell as thewild type, but
had the same ability to inhibit ceramide channels as the wild type. Thisl concentration of added Bcl-xL or mutants was 0.72 μM (A) and 0.86 μM (B). C. Relative
ssed relative to that of the wild-type so that if it is the same as the wild type the result
d by the asterisks.
Fig. 7. Correlation between the ability of mutant Bcl-xL to inhibit MOM permeabilization
by Bax and by ceramide.
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from MOMP due to activated Bax or ceramide.
3.6. Probing the relative importance of ceramide and Bax channels in
apoptosis in intact cells
Both ceramide and Bax form channels that release proteins from the
MIS. These two agents also act synergistically to induce MOMP [17].
However it is unclear which channel-former is used in vivo. The Bcl-xL
mutant proteinswere expressed in cells lackingBcl-xL in order to obtain
some insight into this question. Cells expressing either wild type or one
of three mutants (Y195A, V126Q, V126W) were stimulated to undergo
apoptosis using 7 different chemical stimuli (cisplatin, gemcitabine,
hydrogen peroxide, thapsigargin, doxorubicin, etoposide, or bortezomib)
that activate different apoptotic pathways. A comparable level of expres-
sion ofmutant proteinswas achieved and a dose response curvewas per-
formed for all of the above stimuli. Fig. 8 shows an example of the dose–
response curves. Two doses were selected for detailed statistical analysis,
one in the transition region between no drug effect and the full effect and
another immediately after a maximal effect of the chemical agent was
achieved.
V126W inhibits ceramide channels as well as wild-type Bcl-xL
(Fig. 9) but has only half the potency on Bax channels. In most cases
this mutant was less effective than the wild-type in protecting cells
from apoptosis, consistent with the important role of Bax channels in
the apoptotic process. V126Q is more effective at inhibiting both Bax
and ceramide channels (Figs. 3 and 6); cells expressing V126Q were
often more resistant to death stimuli than the wild type (gemcitabineFig. 8. Relative cell viability after treatment with the indicated amount of bortezomib. Bcl-
xL deﬁcient MEF cells were engineered to stably express either wild type Bcl-xL (WT) or
Bcl-xL point mutants V126W, V126Q, or Y195A.
Fig. 9. A Relative viability of cells expressing the indicated Bcl-xL and induced to undergo
apoptosis with the indicated amount of chemical agent. The signiﬁcant differences are in-
dicated as follows: *, compared to empty vector; #, compared to V126W; $, compared to
wild type (WT); +, compared to V126Q. B Additional apoptosis inducers are listed with
details as in A.
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high dose). Y195A is also more potent at inhibiting Bax channels but
only half as potent on ceramide channels (Figs. 3 and 6). Cells express-
ing Y195A were more sensitive to gemcitabine (low dose), doxorubicin
(high dose), and bortezomib (low dose) than cells expressing V126Q
even though Y195A is a more potent inhibitor of Bax channels (Figs. 9
and 6). In the case of the high dose of bortezomib, cells expressing
Y195A are more sensitive than cells expressing the wild-type Bcl-xL
(Fig. 9B). The results with Y195A provide evidence for the role of cer-
amide channels in cells treated with these compounds. In other cases,
such as thapsigargin treatment, the weaker ability of Y195A to inhibit
ceramide channels had no effect as the cell viability observed with
cells expressing V126Q and Y195A were not different. Thus ceramide
channels may play a role in apoptosis induced by speciﬁc stimuli.
4. Discussion
The surprising ability of a lipid, ceramide, to form large, stable chan-
nels in phospholipid membranes was initially met with skepticism.
Now the evidence supporting the existence of ceramide channels is
overwhelming. This includes recording their properties in deﬁned pla-
nar phospholipid membrane systems [23,52], visualization by electron
microscopy [22], demonstration of the stability of the ceramide channel
model by molecular dynamic simulations [24], and examination of the
elastic properties of these channels by microﬂuidic methods [25]. The
role of these channels in apoptosis was indicated by the ability of cer-
amide to permeabilize the MOM to proteins even when the source of
the mitochondria was the yeast, Saccharomyces cerevisiae, an organism
lacking the Bcl-2 family of proteins [26]. The evidence for this role was
substantially increased by the ﬁndings that Bcl-2, Bcl-xL and CED-9 all
inhibit ceramide channel formation in isolated mitochondria [26]
whereas Bax acts synergistically with ceramide to permeabilize the
MOM [17]. Further support of a speciﬁc regulatory role of ceramide
channels by Bcl-2 family proteins was the ﬁnding that Bcl-xL acts by
interacting with the hydrophobic region of ceramide whereas Bax pref-
erentially interacts with the polar regions [29]. Furthermore, the results
demonstrated that the ability of Bcl-xL to inhibit ceramide channel for-
mation cannot be simply attributed to hydrophobic interactions be-
tween these entities. There is strong speciﬁcity. Bcl-xL strongly
inhibits ceramide channels formed by ceramide with an acyl chain
that is 16, 18 and 20 carbons long but inhibition of channels formed
by ceramide with a 24 carbon chain is much weaker and when that
chain is only 2 carbons long there is no inhibition [8]. This chain length
dependence is physiologically relevant (e.g. ref. [53]). These were not
binding experiments but nevertheless indicated strong speciﬁcity.
Here we actually identify the region of Bcl-xL that binds ceramide and
it turns out to be a similar region to the one that binds Bax.
The direct binding experiments used ﬂuorescently-labeled ceramide
as a surrogate for ceramide channels. The ability of Bcl-xL to bind cer-
amide monomers raises the question of whether Bcl-xLmight be acting
by depleting the free ceramide concentration, rather than binding to the
ceramide channel. However, the amount of ceramide added to themito-
chondrial suspension was 25 to 70 fold higher on amolar basis that Bcl-
xL, making this possibility unlikely. Given that fact, one might wonder
why the excess ceramide does not simply occupy all the sites on Bcl-
xL and act as a competitive inhibitor, interfering with Bcl-xL binding
to the ceramide channel. The answer might reside in the observation
that Bcl-xL binds to the acyl chains of ceramide and typically these are
buried either in the membrane bilayer or in the core of ceramide mi-
celles and are thus unavailable for binding to Bcl-xL. However, accord-
ing to the working model of the ceramide channel (S1), the ceramide
molecules that form the channel are oriented parallel to the plane of
the membrane and organized in columns that span the membrane. The
ceramides at the ends of these columns would have their hydrophobic
tails exposed to the water phase were it not for these being covered by
the surrounding phospholipids tominimize the unfavorable interactionswithwater. However these phospholipids are in a distorted, high-energy
conformation [24]. MD simulations (Andriy Anishkin unpublished re-
sults) show that the ceramide tails at the end of the columns become
transiently exposed, indicating the stressed state of this interface. If
Bcl-xL were to displace these lipids it would bind the hydrophobic tails
of the end ceramide and by doing so could change the structure of the
channel. According to one hypothesis that describes how Bcl-xL binding
destabilizes ceramide channels [29], the binding changes the curvature
of the ceramide columns. MD simulations [24] show that the columns
have a positive curvature resulting in the channel having a somewhat
hourglass shape. This is due to the way the channel interfaces with the
surrounding phospholipids in the bilayer. The neighboring phospho-
lipids that curve towards the channel to cover the hydrophobic ends of
the ceramide columns are under stress and thus pull on the ceramide
columns, bending them. Bcl-xL binding removes this bending force by
displacing the phospholipids. This results inmismatchwith adjacent col-
umns still interacting with phospholipids and thus strain develops that
propagates to the rest of the structure through the hydrogen-bonded
network, thus destabilizing the entire structure. Mutations that weaken
the binding of Bcl-xL to ceramide (ﬂuorescence and MD simulations)
should reduce the ability of Bcl-xL to destabilize ceramide channels and
that was demonstrated in their reduced ability to inhibit ceramide per-
meabilization of the MOM. Altering the position of the ceramide-Bcl-xL
interface, as indicated in theMD simulation,may alter the above hypoth-
esized curvature change and thus the amount of strain and the degree of
destabilization of the channel structure. This explains the correlation be-
tween a shift in the location of ceramide binding to mutant Bcl-xL and a
reduction in the Bcl-xL's ability to inhibit the ceramide-induced MOMP.
In addition to the proposed structural mismatch between adjacent cer-
amide columns, the displacement of the phospholipids by Bcl-xL also un-
balances forces on the channel from the phospholipids in the two
membrane leaﬂets. This should drive ceramide columns to the opposite
side of the membrane and out of the channel, thus reducing channel
size. The Bcl-xL could move from column to column catalyzing the loss
of columns from the channel. There are other possible mechanisms all
of which would require experimentation to include or exclude these
possibilities.
The pro-apoptotic role of ceramide is well established [20,21]
whereas the in-vivo pro-apoptotic role of ceramide channels is not.
Not only do these channels have the right properties, butmitochondrial
ceramide levels have been shown to increase early in apoptosis to levels
sufﬁcient to form ceramide channels. However, these ﬁnding do not
demonstrate that cells actually use ceramide channels during apoptosis.
Indeed, ceramide metabolites were reported [54] to activate Bax and
Bak and induce MOMP. In view of this one might question the role of
ceramide in vivo especially considering the fact that cells lacking both
Bax and Bak are very resistant to apoptosis. But here again the simple
conclusion ismisleading because cells lacking Bax and Bak also fail to in-
crease mitochondrial ceramide levels [16], unlike the parental cells. It
turns out that Bak is required for ceramide synthase-mediated long-
chain ceramide generation during apoptosis. Thus the situation is far
more complex and a more direct approach is needed. Here we report
experimentswithmutants of Bcl-xL that have an altered ability to inhib-
it MOMP induced by either ceramide or Bax. The results show that the
ability of Bcl-xL to inhibit Bax channels is indeed, as expected, important
for Bcl-xL to promote cell survival. However, when the ability of Bcl-xL
to inhibit ceramide channels is reduced, the ability of Bcl-xL to protect
cells from particular death stimuli was also reduced. This lack of protec-
tion from cell death in the mutant Bcl-xL occurred despite it being 15-
foldmore potent at inhibiting Bax channels. Thus it seems that inhibiting
Bax channels alone is insufﬁcient for Bcl-xL to protect from apoptosis
and that under certain conditions ceramide channels take over the role
of releasing proteins frommitochondria. Of course there are alternative
explanations that seem less likely. For instance if Bcl-xLwere to facilitate
the transfer of ceramide between membranes and this transfer were
important to the progress of apoptosis then mutations that weaken
2383K.-T. Chang et al. / Biochimica et Biophysica Acta 1848 (2015) 2374–2384the binding of Bcl-xL to ceramide would also weaken the propensity to
undergo apoptosis. This hypothetical function would not explain the
results with isolated mitochondria but cannot be excluded as a possibil-
ity in the in vivo experiments. Regardless role of ceramide channels
needs to be considered when interpreting experimental results.
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